ZOLL Enrolls First Patient in Groundbreaking SSCORE Commercial Registry at Minneapolis Heart Institute at Abbott Northwestern Hospital (Minneapolis, MN)
Study designed to provide confirmational data on clinical benefits of SuperSaturated Oxygen Therapy for heart attack patients and financial benefits for healthcare organizations
“These patients with LAD occlusion are at significant risk. Opening the artery is the first step but using SSO2 to further decrease infarct size is vital. This patient had an acute proximal LAD occlusion and I wanted to give him the best chance of preserving his heart function,” stated Dr.
“Enrolling the first patient in the SSCORE study marks a significant milestone in advancing the use of SuperSaturated Oxygen Therapy to treat the most severe heart attacks," said
Patients with LAD STEMI heart attacks have higher mortality rates than those with other types of heart attacks. SSO2 Therapy is the first and only FDA-approved treatment that has been clinically proven to significantly reduce damage to cardiac muscle in heart attack patients after coronary angioplasty with stenting.1 The extent of damaged cardiac muscle is a strong predictor of future outcomes like rehospitalization and the development of heart failure.2
SSO2 Therapy is indicated as an adjunct for patients who suffer LAD STEMI and are treated with traditional stenting within six hours of chest pain onset. The therapy delivers high levels of dissolved oxygen (7–10 times the amount normally found in the bloodstream) directly to the damaged heart muscle immediately after the coronary artery has been successfully opened via angioplasty and stenting. Multiple clinical trials have demonstrated the safety and efficacy of SSO2 Therapy to reduce infarct size, a strong predictor of subsequent outcomes.1, 3 -6
“The focus on reducing infarct size and improving microvascular function with SSO2 in the cath lab versus palliation of disease is a logical strategy that has been long awaited in this field,” said Dr.
About ZOLL
ZOLL, an Asahi Kasei company, develops and markets medical devices and software solutions that help advance emergency care and save lives, while increasing clinical and operational efficiencies. With products for defibrillation and cardiac monitoring, circulation enhancement and CPR feedback, supersaturated oxygen therapy, data management, ventilation, therapeutic temperature management, and sleep apnea diagnosis and treatment, ZOLL provides a comprehensive set of technologies that help clinicians, EMS and fire professionals, as well as lay rescuers, improve patient outcomes in critical cardiopulmonary conditions. For more information, visit www.zoll.com.
About Asahi Kasei
Asahi Kasei is also dedicated to sustainability initiatives and is contributing to reaching a carbon neutral society by 2050. To learn more, visit https://www.asahi-kasei.com/sustainability/.
1 Stone GW, et al. Circ Cardiovasc Intervent 2009;2:366-75.
2 Stone GW et al. J Am Coll Cardiol. 2016;67(14):1674–83.
3 O’Neill WW, et al. Jour of Am Coll Cardiol. 2007;50: 5:397-405.
4 David SW, et al. Catheter Cardiovasc Interv. 2018;1–9.
5 https://www.cms.gov/Medicare/Coding/ICD10/Downloads/2020-ICD-10-PCS-Guidelines.pdf
6 Chen S, et al. Catheter Cardiovasc Interv. 2020; 1–7.
Copyright © 2024 ZOLL Medical Corporation. All rights reserved. ZOLL and
View source version on businesswire.com: https://www.businesswire.com/news/home/20240923128741/en/
+1 (978) 805-6561
media@zoll.com
Source: